N-[2-(4-Hydroxy-phenyl)-ethyl]-4-phenyl-butyramide | 193220-18-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: N-[2-(4-Hydroxy-phenyl)-ethyl]-4-phenyl-butyramide
• 英文别名: N-[2-(4-Hydroxyphenyl)ethyl]benzenebutanamide；N-[2-(4-hydroxyphenyl)ethyl]-4-phenylbutanamide
• CAS: 193220-18-7
• 化学式: C₁₈H₂₁NO₂
• 分子量: 283.37
• InChiKey: XLYGGBRJCSEVDY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-[2-(4-Hydroxy-phenyl)-ethyl]-4-phenyl-butyramide 在 lithium aluminium tetrahydride 、 碳酸氢钠 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 31.0h， 生成 N-ethyl-N-[2-(4-hydroxyphenyl)ethyl]-4-phenylbutylamine
  参考文献：
  名称：

  Structure−Activity Relationships for a Series of Bis(phenylalkyl)amines:  Potent Subtype-Selective Inhibitors of N-Methyl-d-aspartate Receptors

  摘要：

  A series of bis(phenylalkyl)amines, structural analogues of ifenprodil and nylidrin, were synthesized and tested for antagonism of N-methyl-D-aspartate (NMDA) receptors. Potency and subunit selectivity were assayed by electrical recordings in Xenopus oocytes expressing three binary combinations of cloned rat NMDA receptor subunits: NR1A expressed in combination with either NR2A, NR2B, or NR2C. The bis(phenylalkyl)amines were selective antagonists of NR1A/2B receptors. Assayed under steady-state conditions, the most potent of these, N-[2-(4-hydroxyphenyl)ethyl]-5-phenylpentylamine hydrochloride (20), has an IC50 value of 8 nM and > 1000-fold selectivity with respect to NR1A/2A and NR1A/2C receptors. The structure-activity relationship of the bis(phenylalkyl)amine series indicates that the piperidine ring and alkyl chain substitutions common to NR2B-selective antagonists such as ifenprodil, CP 101,606, and Ro 25-6981 are not necessary to generate potent and selective ligands. The primary determinants of potency are the phenolic OH group, acting as a hydrogen bond donor, the distance between the two rings, and an electrostatic interaction between the receptor and the basic nitrogen atom. This study provides a framework for designing structurally novel NR2B-selective antagonists which may be useful for treatment of a variety of neurological disorders.

  DOI：

  10.1021/jm980235+
• 作为产物：
  描述：

  对羟基苯乙胺 、 4-苯基丁酸 在 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 27.0h， 以92%的产率得到N-[2-(4-Hydroxy-phenyl)-ethyl]-4-phenyl-butyramide
  参考文献：
  名称：

  Structure−Activity Relationships for a Series of Bis(phenylalkyl)amines:  Potent Subtype-Selective Inhibitors of N-Methyl-d-aspartate Receptors

  摘要：

  A series of bis(phenylalkyl)amines, structural analogues of ifenprodil and nylidrin, were synthesized and tested for antagonism of N-methyl-D-aspartate (NMDA) receptors. Potency and subunit selectivity were assayed by electrical recordings in Xenopus oocytes expressing three binary combinations of cloned rat NMDA receptor subunits: NR1A expressed in combination with either NR2A, NR2B, or NR2C. The bis(phenylalkyl)amines were selective antagonists of NR1A/2B receptors. Assayed under steady-state conditions, the most potent of these, N-[2-(4-hydroxyphenyl)ethyl]-5-phenylpentylamine hydrochloride (20), has an IC50 value of 8 nM and > 1000-fold selectivity with respect to NR1A/2A and NR1A/2C receptors. The structure-activity relationship of the bis(phenylalkyl)amine series indicates that the piperidine ring and alkyl chain substitutions common to NR2B-selective antagonists such as ifenprodil, CP 101,606, and Ro 25-6981 are not necessary to generate potent and selective ligands. The primary determinants of potency are the phenolic OH group, acting as a hydrogen bond donor, the distance between the two rings, and an electrostatic interaction between the receptor and the basic nitrogen atom. This study provides a framework for designing structurally novel NR2B-selective antagonists which may be useful for treatment of a variety of neurological disorders.

  DOI：

  10.1021/jm980235+

文献信息

• [EN] SUBTYPE-SELECTIVE NMDA RECEPTOR LIGANDS AND THE USE THEREOF<br/>[FR] LIGANDS DU RECEPTEUR N-METHYL-D-ASPARTATE SELECTIFS DE SOUS-TYPE
  申请人：STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON

  公开号：WO1997023202A1

  公开（公告）日：1997-07-03

  (EN) The invention relates to subtype-selective NMDA receptor ligands and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's diseae, Parkinson's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, chronic pain, glaucoma, CMV retinitis, urinary incontinence and inducing anesthesia, as well as for enhancing cognition, treating or preventing opiate tolerance, treating or preventing aminoglycoside antibiotic induced hearing loss, and treating opiate withdrawal.(FR) Cette invention a trait à des ligands du récepteur N-méthyl-D-aspartate (NMDA) sélectifs de sous-type et à leur utilisation dans le traitement ou la prévention de la dépopulation neuronale associée à un ictus, une ischémie, une lésion du système nerveux central, une hypoglycémie et à un acte chirurgical, ainsi que dans le traitement de maladies neurodégénérescentes, au nombre desquelles la maladie d'Alzheimer, la sclérose latérale amyotrophique, les maladies d'Huntington et de Parkinson ainsi que le syndrome de Down. Ces ligands sont également utilisés dans le traitement et la prévention des conséquences préjudiciables d'une stimulation excessive d'acides aminés excitateurs, le traitement de l'anxiété, de psychoses, de convulsions, de douleurs chroniques, du glaucome, de la rétinite à cytomégalovirus, de l'incontinence urinaire et pour le déclenchement de l'anesthésie ainsi que comme tonique cérébro-actif. Ces ligands sont, en outre, utilisés dans le traitement et la prévention de l'accoutumance opiacée et le traitement du sevrage des dépendances aux opiacés ainsi que pour le traitement et la prévention du déficit auditif provoqué par des aminoglycosides.

  本发明涉及亚型选择性NMDA受体配体及其在治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元丢失，以及治疗包括阿尔茨海默病、肌萎缩侧索硬化症、亨廷顿病、帕金森病和唐氏综合症在内的神经退行性疾病，治疗或预防兴奋性氨基酸过度刺激的不良后果，治疗焦虑、精神病、癫痫、慢性疼痛、青光眼、CMV视网膜炎、尿失禁和诱导麻醉，以及增强认知能力，治疗或预防阿片类药物耐受性，治疗或预防氨基糖苷类抗生素引起的听力损失，和治疗阿片类药物戒断症状的用途。
• Structure−Activity Relationships for a Series of Bis(phenylalkyl)amines:  Potent Subtype-Selective Inhibitors of <i>N</i>-Methyl-<scp>d</scp>-aspartate Receptors
  作者：Amir P. Tamiz、Edward R. Whittemore、Zhang-Lin Zhou、Jin-Cheng Huang、John A. Drewe、Jie-Cheng Chen、Sui-Xiong Cai、Eckard Weber、Richard M. Woodward、John F. W. Keana

  DOI：10.1021/jm980235+

  日期：1998.8.1

  A series of bis(phenylalkyl)amines, structural analogues of ifenprodil and nylidrin, were synthesized and tested for antagonism of N-methyl-D-aspartate (NMDA) receptors. Potency and subunit selectivity were assayed by electrical recordings in Xenopus oocytes expressing three binary combinations of cloned rat NMDA receptor subunits: NR1A expressed in combination with either NR2A, NR2B, or NR2C. The bis(phenylalkyl)amines were selective antagonists of NR1A/2B receptors. Assayed under steady-state conditions, the most potent of these, N-[2-(4-hydroxyphenyl)ethyl]-5-phenylpentylamine hydrochloride (20), has an IC50 value of 8 nM and > 1000-fold selectivity with respect to NR1A/2A and NR1A/2C receptors. The structure-activity relationship of the bis(phenylalkyl)amine series indicates that the piperidine ring and alkyl chain substitutions common to NR2B-selective antagonists such as ifenprodil, CP 101,606, and Ro 25-6981 are not necessary to generate potent and selective ligands. The primary determinants of potency are the phenolic OH group, acting as a hydrogen bond donor, the distance between the two rings, and an electrostatic interaction between the receptor and the basic nitrogen atom. This study provides a framework for designing structurally novel NR2B-selective antagonists which may be useful for treatment of a variety of neurological disorders.